Jobs
-
AstraZeneca has announced that it will “expand the savings programs for its entire US inhaled respiratory portfolio,” capping costs at $35 per month for “eligible patients” as of June 1, 2024, while noting that “terms… Read more . . .
-
Kindeva Drug Delivery has named former West Pharmaceutical Services Senior Director, Business and Technical Operations, Jennifer Riter as VP of Analytical Services. Earlier this year, Kindeva announced the launch of its new analytical services business, which… Read more . . .
-
According to Optinose, the FDA has approved the company’s sNDA to extend use of Xhance fluticasone propionate nasal spray to include the treatment of chronic sinusitis without nasal polyps. Xhance was approved by the FDA for… Read more . . .
-
Device manufacturer Aptar Pharma announced that it will expand its production facility in Congers, NY, USA, including a significant increase in its capacity for manufacturing the Unidose (UDS) nasal delivery system. The expansion includes new cleanroom… Read more . . .
-
Inhalon Biopharma has announced the publication of two articles that present data from preclinical studies of the company’s inhaled “muco-trapping” technologies. The first, published in the journal Advanced Science, describes a study of nebulized delivery of… Read more . . .
-
AstraZeneca today announced the initiation of the Phase 3 ATHLOS and THARROS trials evaluating the effects of Breztri Aerosphere budesonide / glycopyrronium / formoterol fumarate MDI on cardiopulmonary parameters and outcomes (including death) in COPD… Read more . . .
-
MannKind Corporation announced that it recently presented initial data from a meal challenge that was part of the Phase 4 INHALE-3 trial of Afrezza insulin DPI plus basal insulin injections versus standard of care in… Read more . . .
-
Vast Therapeutics has announced the appointments of former Aradigm Senior Medical Director Paul Bruinenberg as Chief Medical Officer and Chris Polage as Medical Director in preparation for clinical development of its ALX1 inhalation solution. Bruinenberg was most recently… Read more . . .
-
Boehringer Ingelheim said that “eligible patients” will pay no more than $35 per month for BI inhalers, including Atrovent HFA ipratropium MDI, Combivent Respimat ipratropium / albuterol SMI, Spiriva HandiHaler tiotropium DPI, Spiriva Respimat tiotropium SMI, Stiolto Respimat tiotropium / olodaterol… Read more . . .
-
Researchers at the University of Western Australia have received a A$500,000 grant from the CUREator biotech incubator for development of the Spritz-OM probiotic nasal spray for the prevention of ear infections in children. The grant… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland